ARCHIVES

FDA Approves Evista for Breast Cancer Risk Reduction.

This article is from The Cancer Letter archive.

Vol. 33 No. 33 | September 14, 2007

Download PDF Visit The Full Archive

Related Articles

NCI Needs 100 SBIR Contracts By April 1 To Avoid Losing $5 Million; NIH Objects To DCT Comments

March 22, 1985

In Brief: FDA To Review Preclinical Testing, Phase I Protocols At Open Advisory Group Meeting

November 14, 1975

2015: “A Challenge For Our Generation,” AACR Says

July 18, 2003

Becker, Brown Testify On Biomedical Funding, Manpower Needs

March 23, 1990

Perifosine Increases PFS In Phase II Study

December 30, 2011

BioSeek Awarded NIH SBIR For Compound Validation.

July 4, 2003